FDA Accepts Merck New Drug Application for Sugammadex Sodium Injection
Neuromuscular blockade, which is used by anesthesiologists to relax muscles during surgery, is revered by the sugammadex sodium injection. Upon approval, this substance would be one of the first medicines of its kind to be used in the U.S. surgical setting.
The FDA previously rejected the NDA in 2008 and requested more data on allergic reactions and bleeding events. The application has now been deemed complete for review.
More Articles on Anesthesia:
Novitas Expected to Revise Limits to Anesthesia Coverage
6 ASC Characteristics That Matter to Anesthesiologists
Children's National Medical Center Names Joint Chief Medical Officers
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- This peptide may treat bacterial infections: 3 study insights
- Crohn's & Colitis Foundation shares results from IBD Qorus pilot program: 3 notes
- Patients over 75 years old may not benefit from colonoscopy: 4 study insights
- FDA approves Janssen Biotech's STELARA; Boston Scientific leads GI/endoscopic device market & more: 7 GI company key notes
- Outpatient hip resurfacing lowers cost up to 60%: 5 study insights